First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Advanced Cancer Clinical Trial

Official title:

Phase I/IIa First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04335253
• Other study ID #: IO-002
• Status: Completed
• Phase: Phase 1
• Start date: February 18, 2020
• Est. completion date: April 7, 2022

Study information

• Verified date: September 2021
• Source: iTeos Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.

Description:

Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will consist in a dose-escalation phase to determine the MTD, the RP2D, and the safety of EOS884448 in participants with advanced cancers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 7, 2022
• Est. primary completion date: April 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be willing to provide a signed written informed consent for the trial and consent for biopsies before and during administration of EOS884448

2. Be more than18 years of age on day of signing informed consent.

3. Have histologically or cytologically confirmed advanced or metastatic cancer for whom no standard treatment is further available

4. Have evaluable disease, per RECIST v1.1 for solid tumor escalation or other criteria if indicated

5. Have an ECOG performance status of Grade 0 to 1.

6. Have adequate organ function.

7. Agree to use adequate contraception during the treatment if required.

Exclusion Criteria:

1. Has received any anti-cancer therapy, unless at least 4 weeks (or 5 half-lives, whichever is shorter) since the last dose.

2. Has undergone major surgery within 5 weeks before initiating treatment.

3. Has received prior radiotherapy within 2 weeks of start of IP.

4. Has toxicity (except for alopecia) related to prior anti-cancer therapy, unless the toxicity is resolved, returned to baseline or Grade 1, or deemed irreversible.

5. Has known CNS metastases.

6. Has any condition requiring concurrent use of systemic immunosuppressants or corticosteroids.

7. Has uncontrolled or significant cardiovascular disease.

8. Has received vaccine containing live virus within 4 weeks.

9. Has known active or chronic viral hepatitis.

10. Has any known or underlying medical, psychiatric condition, and/or social situations that, in the opinion of the investigator, would limit compliance with study requirements.

Related Conditions & MeSH terms

• Advanced Cancer
• Neoplasms

Intervention

Drug:
• EOS884448
Multiple Ascending Dose

Locations

Country	Name	City	State
Belgium	GZA Ziekenhuizen campus Sint-Augustinus	Antwerp
Belgium	Cliniques universitaires St Luc-UCL	Brussels
Belgium	Institut Jules Bordet	Brussels
Belgium	Universitair Ziekenhuis Gent	Gent

Sponsors (1)

Lead Sponsor	Collaborator
iTeos Belgium SA

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants with Adverse Events		From first dose date to 90 days after the last dose (up to 48 weeks)
Primary	Percentage of participants who experience a Dose Limiting Toxicity		From first study treatment administration through Day 28
Primary	Define the recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced tumors.		up to 48 weeks
Secondary	Mean and median Area under the curve (AUC) of EOS884448 at each dose level		up to 48 weeks
Secondary	Mean and median Maximum concentration (Cmax) of EOS884448 at each dose level		up to 48 weeks
Secondary	Percentage of participants with Objective Response as determined by Investigator according to RECIST v1.1or per other specific response criteria according to their tumor type.		From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 48 weeks)
Secondary	Percentage of participants with anti-drug antibodies to EOS884448		Recorded at baseline (screening), during the first 4 cycles of treatment (4 months), at end of treatment, and 30 and 90 days post last dose (approximately 48 weeks)